HR.796: To amend the Federal Food, Drug, and Cosmetic Act to require a warning label advising that the effects of mifepristone can be counteracted, to amend the Public Health Service Act to establish a hotline to provide information to women seeking to counteract the effects of mifepristone, and for other purposes.
Sponsors
12 bill sponsors
-
Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
Actions
2 actions
Date | Action |
---|---|
Jan. 28, 2025 | Introduced in House |
Jan. 28, 2025 | Referred to the House Committee on Energy and Commerce. |
Corporate Lobbying
0 companies lobbying
None found.
* Note that there can be significant delays in lobbying disclosures, and our data may be incomplete.
Potentially Relevant Congressional Stock Trades
No relevant congressional stock trades found.